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Кількість хворих з артеріальною гіпертензією (АГ) продовжує збільшуватись. Суттєвим негативним 
наслідком артеріальної гіпертензії є структурні, метаболічні та функціональні порушення у тканинах 
міокарду, судин та інших органів, зокрема зміна вмісту жирних кислот (ЖК) та їх співвідношення.  
Мета роботи – дослідити зміну жирнокислотного складу ліпідів сироватки крові та тканин щурів з 
артеріальною гіпертензією під дією нової оригінальної сполуки - похідного 1,3-оксазол-4-іл-фосфонової 
кислоти (скорочена назва - похідне оксазолу).  
Матеріали та методи. Дослідження проводили на білих статевозрілих щурах. Артеріальну гіпертензію 
моделювали шляхом сольового навантаження – сольового пиття (1 % розчин натрію хлориду) з вільним 
доступом до нього впродовж 21 доби. Тваринам з 14-ї доби вводили похідне оксазолу в дозі 25 мг/кг вну-
трішньоочеревинно, один раз на добу, щоденно, протягом 7 діб. Вміст ЖК ліпідів відцентрифугованої 
сироватки крові та гомогенізованих у 0,9 % фізіологічному розчині NaCl тканин визначали за допомогою 
газохроматографічного аналізу.  
Результати та їх обговорення. Введення похідного оксазолу на фоні підвищеного артеріального тиску 
у щурів достовірно не впливало на суму НЖК та ННЖК в сироватці крові на відміну від групи щурів з АГ 
за рахунок тенденції до відновлення вмісту стеаринової кислоти, проте змінений вміст лінолевої та 
арахідонової кислот практично не відрізнявся від значень останніх в контрольній крупі за даних умов ек-
сперименту. В аорті спостерігалось відновлення вмісту пальмітинової, стеаринової, лінолевої та арахі-
донової кислот. В серці встановлено зміну вмісту лінолевої та арахідонової кислот у зворотньому на-
прямку порівняно з контрольною групою. 
Висновки. Введення похідного оксазолу в дозі 25 мг/кг (ЕD50) внутрішньоочеревинно один раз на добу 
протягом 7 днів при одночасному моделюванні артеріальної гіпертензії шляхом сольового навантажен-
ня вцілому не викликало негативних змін та призводило до відновлення ліпідних показників НЖК, ННЖК 
та ПНЖК 
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1. Introduction 
Today, the global pharmaceutical market presents 
a wide range of antihypertensive drugs. However, the 
number of patients with arterial hypertension (AH) con-
tinues to increase. This disease causes annually about 
12.8 % of deaths in the world and leads to a significant 
deterioration in the quality of life of patients due to the 
severity of the consequences of its ineffective treatment: 
myocardial infarction, stroke, chronic renal failure and 
peripheral arterial disease [1, 2]. The accelerated dynamics 
of hypertension is an urgent problem of modern medicine, 
which is exacerbated by demographic aging of the popula-
tion and behavioural risk factors, including malnutrition, 
hypodynamia, and permanent stress conditions [3]. 
 
2. Formulation of the problem in a general 
way, the relevance of the theme and its connection 
with important scientific and practical issues 
Despite the presence of a significant arsenal of 
drugs with a different mechanism of action, the effec-
tiveness of antihypertensive therapy remains low. In par-
ticular, in Ukraine, this figure is only 8.1 % in rural areas 
and 18.7 % in the urban population, which requires further 
detailed study of the pathogenesis of this disease and the 
search for new compounds to achieve the target blood 
pressure levels by acting directly on the target, which is 
the cause of development arterial hypertension [4, 5].  
3. Analysis of recent studies and publications in 
which a solution of the problem are described and to 
which the author refers 
Substantial negative effects of arterial hyperten-
sion are structural, metabolic and functional disorders in 
the tissues of the myocardium, vessels and other organs, 
in particular, changes in the content of fatty acids (FA) 
and their ratios [6, 7]. Changes in lipid metabolism in 
hypertension are associated with a decrease in the con-
sumption of fatty acids by the body due to increased 
absorption and an imbalance between glucose and FA in 
mitochondria [8]. It is known that hypertension rats in 
blood plasma most change the content of arachidonic, 
palmitic, linoleic, pentadecanoic and margaric acids [9]. 
Therefore, an important task of modern antihypertensive 
therapy is the search for molecules and the development 
of new antihypertensive drugs, which can not only nor-
malize blood pressure, but also correct these pathological 
changes. 
 
4. The field of research considering the general 
problem, which is described in the article 
The derivative of 1,3-oxazole-4-yl-phosphonic ac-
id (abbreviated name - oxazole derivative) is a novel, 
original compound, which, according to the results of 
previous experimental studies, in vitro and in vivo has a 
vasodilating effect and is promising for further study as a 
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low-toxic antihypertensive agent, but its influence on the 
fatty acid composition of lipids in the blood to this time 
was not investigated [10, 11].  
 
5. Formulation of goals (tasks) of article 
The aim of the work was to investigate the 
changes in the fatty acid composition of blood serum 
lipids and tissues of rats with arterial hypertension under 
the action of oxazole derivatives. 
 
6. Presentation of the main research material 
(methods and objects) with the justification of the 
results 
Materials and methods. The studies were con-
ducted on white, sexually mature rats with an average 
weight of 181.8±3.54 g. Animal rearing and care was 
carried out in accordance with the European Union Di-
rective 2019/10/63 EU on the protection of vertebrate 
animals used for experimental and other scientific pur-
poses and, accordingly, to the Law of Ukraine No. 3447-
ІV "On the Protection of Animals from Cruel Treatment" 
[12, 13]. 
Arterial hypertension (AH) was modelled with 
salt loading – salt drink (1 % solution of sodium chlo-
ride) with free access to it for 21 days [14]. The mean 
blood pressure level in non-sarcotised rats was recorded 
by sphygmomanometric method using a specialized cuff 
with a pulse sensor mounted on the rat's tail and an anal-
ysis of the periodicity of blood flow oscillations at the 
UgoBasile installation (Italy, 2005). 
With the random sampling technique, rats were 
divided into 3 groups of 7 individuals in each. Group 1 
included intact rats. Group 2 (blank) includes rats, which 
formed a model of stable AH during 21 days by salt 
loading. Group 3 includes rats with elevated blood pres-
sure of 8 % and above at 14 days after the start of salt 
loading. Animals of this group from the 14th day were 
given a dose of 25 mg / kg intraperitoneally, once, daily 
for 7 days. This group of animals is formed to determine 
the effect of 1,3-oxazole-4-yl-phosphonic derivative in 
order to prevent the development of hypertension or 
decrease the degree of hypertension.  
The rats were decapitated with subsequent extir-
pation of the heart, aorta, liver, kidneys and blood collec-
tion. The content of liquid lipids of centrifuged blood 
serum and homogenized in 0.9 % saline NaCl tissue was 
determined by gas chromatographic analysis according to 
the generally accepted method [15]. The peaks of fatty 
acids were identified by comparing with the time 
maintenance of the peaks of standard FA. An assay of the 
ratio of fatty acids of lipids in % was carried out by the 
method of normalizing the peaks of the peaks of ethyle-
nic derivatives of FA [16]. 
Changes in fatty acid composition of serum lipids 
were evaluated by the definition of the quantitative con-
tent of the 9 most informative FA: myristic C14:0, penta-
decane C15:0, palmitinic C16:0, margaric C17:0, stearic C18:0, 
amounting to SFA, and oleic C18:1, linoleic C18:2, linolen-
ic C18:3, arachidonic C20:4, amounting to the MUFA. Lin-
oleic С18:2, linolenic С18:3 and arachidonic С20:4 FA belong 
to the sum of polyunsaturated fatty acids (PUFA) and are 
defined as irreplaceable [15]. 
Statistical data was processed using the BioStat 
2009 v 5.8.4 licensing program (produced by Analyst 
Soft). To compare mean values of the samples, a simple 
Student's coefficient was used, or a two-sample t-test 
with different dispersions (heteroscedastic). Changes in 
indicators were considered statistically significant at a 
significance level of more than 95 % (P<0.05). 
Results of the research. Studies have shown that 
in the modelling of persistent arterial hypertension by the 
salt load in Group 2, the fatty acid composition of blood 
serum lipids and tissues of the investigated organs signif-
icantly changed in comparison with the group of normo-
tensive intact rats (Tab.1). In particular, serum levels of 
stearic acid increased by 28.4 % (p<0.05), resulting in an 
increase in the amount of SFA by 11.2 % (p <0.05). At 
the same time, the content of arachidonic acid increased 
by almost 5 times (p <0.05), but the amount of UFA and 
PUFA decreased in the form of a tendency due to a de-
crease in the content of linoleic acid. In the aorta, an 
increase in the content of myristic (by 8 times, p<0.05) 
and palmithinic acid (40.4 %, p<0.05) and reduction in 
the content of stearic acid (17.8 %, p<0.05), linoleic 
(28.9 %, p<0.05) and arachidone (25.4 %, p<0.05) acids. 
Accordingly, an increase in the amount of SFA and a 
reduction in the amount of UFA, PUFA in the aorta were 
noted. In the heart, only a decrease in the content of lino-
leic and an increase in the content of arachidonic acids 
was observed, respectively, by 25.8 % (p <0.05) and  
16.9 % (p <0.05), and in the liver the increase in the 
content of oleic (17.1 %, p <0.05), linoleic acids (by  
29.1 %, p <0,05) and reduction of arachidonic acid con-
tent (by 28,6 %, p<0.05). At the same time, in the kid-
neys, a 22.2 % (p<0.05) decrease in the amount of SFA 
was observed due to myristic and palmitic acid and a 
corresponding increase in the UFA value by 16.7 %  
(p <0.05) due to oleic, linoleic and arachidonic acids . 
From Tabl. 2, it can be seen that the administra-
tion of the oxazole derivative in the background of 
elevated blood pressure in rats did not significantly 
affect the amount of SFA and UFA in serum, unlike the 
group of rats with hypertension due to the tendency to 
restore the stearic acid content, but the changed content 
of linoleic and arachidonic acids was virtually non-
existent it differed from the values of the latter in the 
blank group under the given experimental conditions. 
Restoration of the content of stearic, linoleic and ara-
chidonic acids in the aorta and reduction of the palmitic 
acid content to the baseline level was observed. In the 
heart, the change in the content of linoleic and arachi-
donic acids in the reverse direction compared with the 
blank group was established. Thus, the content of lino-
leic acid, by contrast, was higher by 14.4 % (p <0.05), 
and the content of arachidonic acid was lower by  
18.4 % (p <0.05) compared to normalizing rats. In the 
kidneys and the liver, all the lipid fatty acid composi-










Fatty acid composition of rat lipid tissues and serum in experimental arterial hypertension, % (M±m, n=7) 
Nomenclature of 
FA 





















Myristic С14:0 0.3±0.1 0.3±0.1 3.3±0.5* 0.4±0.1 0.6±0.1 0.4±0.1 1.1±0.1* 3.1±0.5 0.4±0.1 0.3±0.1 
Pentadecane С15:0 0.4±0.1 0.2±0.1 0.3±0.1 0.5±0.1 1.6±0.3 1.6±0.5 0.4±0.1 0.4±0.1 0.4±0.1 0.3±0.1 
Palmitinic С16:0 26.4±1.3 25.3±1.5 38.6±1.3* 27.5±1.5 19.5±1.5 18.3±1.5 21.2±1.0* 29.4±1.5 19.1±0.1 21.3±1.3 
Margaric С17:0 0.4±0.1 0.3±0.1 0.3±0.1 0.4±0.1 0.6±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.3±0.1 
Stearic С18:0 11.3±1.0* 8.8±1.0 11.1±1.0* 13.5±1.0 9.3±0.5 9.0±1.0 10.2±0.5 9.5±0.5 6.6±0.5 6.1±0.5 
Oleic С18:1 15.2±1.0 15.6±1.3 18.4±0.6 18.7±0.7 15.3±0.7 13.9±1.0 14.8±0.7* 17.2±1.0 15.1±1.0* 12.9±1.0 
Linoleic С18:2 44.2±1.5* 49.0±1.5 23.1±1.0* 32.5±1.5 22.1±1.0* 29.8±1.5 24.8±0.5* 28.1±1.5 35.9±1.5* 27.8±1.5 
Linolenic С18:3 0.4±0.1 0.2±0.1 0.3±0.1 0.5±0.1 0.6±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.5±0.1 
Arachidonic С18:4 1.4±0.5* 0.3±0.1 4.4±0.5* 5.9±0.8 30.5±1.0* 26.1±1.5 26.7±1.0* 11.3±1.0 21.7±1.5* 30.4±1.5 
∑SFA 38.8±1.8* 34.9±1.8 53.6±1.5* 42.3±1.6 31.6±2.0 29.7±1.8 33.3±1.5* 42.8±2.0 26.9±1.6 28.3±1.8 
∑UFA 61.2±1.8 65.1±1.8 46.4±1.5* 57.7±1.6 68.5±2.0 70.3±1.8 66.5±1.5* 57.0±2.0 73.1±1.6 71.7±1.8 
∑PUFA 46.0±1.5* 49.5±1.5 27.8±1.3* 38.9±1.5 53.2±1.8 56.3±1.6 51.7±1.3* 39.8±1.6 58.0±1.3 58.7±1.5 
Note: * – p <0.05 relative to the intact group (group No. 1) 
 
Table 2 
Influence of 1,3-oxazole-4-yl-phosphonic acid derivative on fatty acid composition of rat lipid tissues and serum in 
experimental arterial hypertension, % (M±m, n=7) 
Nomenclature 
of FA 




















Myristic С14:0 0.5±0.1 0.3±0.1 3.1±0.5* 0.4±0.1 0.4±0.1 0.4±0.1 2.4±0.5 3.1±0.5 0.3±0.1 0.3±0.1 
Pentadecane 
С15:0 
0.5±0.1 0.2±0.1 0.4±0.1 0.5±0.1 1.1±0.5 1.6±0.5 0.4±0.1 0.4±0.1 0.3±0.1 0.3±0.1 
Palmitinic 
С16:0 
28.3±1.0 25.3±1.5 30.1±1.5 27.5±1.5 17.4±1.0 18.3±1.5 24.6±1.0* 29.4±0.1 20.8±1.0 21.3±1.3 
Margaric 
С17:0 
0.5±0.1 0.3±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.3±0.1 0.3±0.1 
Stearic С18:0 10.9±0.5 8.8±1.0 14.0±1.0 13.5±1.0 8.4±1.0 9.0±0.1 10.8±0.5 9.5±0.5 8.4±0.7 6.1±0.5 
Oleic С18:1 14.8±0.6 15.6±1.3 18.1±1.0 18.7±0.7 16.3±0.5 13.9±1.0 19.2±0.8 17.2±1.0 14.5±1.0 12.9±1.0 
Linoleic С18:2 42.2±1.0* 49.0±1.5 28.0±1.5* 32.5±1.5 34.1±1.0* 29.8±1.5 31.4±0.5 28.1±1.5 30.1±1.3 27.8±1.5 
Linolenic 
С18:3 
0.6±0.1* 0.2±0.1 0.4±0.1 0.5±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.4±0.1 0.5±0.1 
Arachidonic 
С18:4 
1.5±0.5* 0.3±0.1 5.5±0.5 5.9±0.8 21.3±1.0* 26.1±1.5 10.3±1.0 11.3±1.0 24.9±1.5 30.4±1.5 
∑SFA 40.7±1.5 34.9±1.8 48.0±1.8* 42.3±1.6 27.7±2.0 29.7±1.8 38.6±1.5 42.8±2.0 30.1±1.5 28.3±1.8 
∑UFA 59.1±1.5 65.1±1.8 52.0±1.8 57.7±1.6 72.1±2.0 70.3±1.8 61.3±1.5 57.0±2.0 69.9±1.5 71.7±1.8 
∑PUFA 44.3±1.3* 49.5±1.5 33.9±1.5* 38.9±1.5 55.8±1.8 56.3±1.6 42.1±1.3 39.8±1.6 55.4±1.3 58.7±1.5 
Note: * – p <0.05 relative to the intact group (group No. 1) 
 
Discussion of results. The established fact of in-
creasing the amount of SFA in the kidneys compared 
with the blank group after the administration of the 1,3-
oxazole-4-yl-phosphonic acid derivative may indicate the 
ability of the compound to stabilize cell membranes and 
inhibit free radical oxidation during the development of 
modulation-induced arterial hypertension inositol lipid 
cycle and signal system of the cell [17]. 
The effect of the oxazole derivative on the in-
crease of arachidonic acid content by 25.0 % (p <0.05) in 
comparison with hypertensive rats in the aorta may be 
related to one of the mechanisms of vasodilating effect of 
the test compound, since arachidonic acid acts as a pre-
cursor in the synthesis of prostaglandin E2 (PGE2), 
which, in turn, interacts with receptors of type EP2, 
causes vasodilation [18]. At the same time, it is logical to 
increase the content of linoleic acid in the aorta as a pre-
cursor to the synthesis of arachidone. On the other hand, 
a decrease in the content of the latter in the heart and 
kidneys after the introduction of the derivative of oxazole 
may indicate the restorative ability of the test compound 
to reduce lipid peroxidation in the abovementioned tis-
sues. A similar effect was found in β-blockers that exhib-
it cardioprotective and nephroprotective effects [9, 19].  
 
7. Conclusions from the conducted research 
and prospects for further development of this field 
1. Conducted studies showed a pronounced effect 
of 1,3-oxazole-4-yl-phosphonic acid derivative on fatty 
acids of serum lipids of blood and tissues of rats with 
elevated blood pressure in the modelling of arterial hy-
pertension by salt loading. 
2. The introduction of the test compound at a dose 
of 25 mg / kg (ED50) intraperitoneally once daily for 7 
days with simultaneous simulation of arterial hyperten-
sion by salt load did not cause any adverse changes in 
general and led to the restoration of lipid parameters of 
SFA, UFA and PUFA. 
3. The established fact of the influence of the de-
rivative of oxazole on the composition of FA lipids is the 
basis for further study of its mechanisms of action with a 
possible prospect of studying as an antihypertensive drug. 
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